Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Cardiologists who Implant TAXUS Stents (US)

Articles with lock require a subscription to GLG News | Request a free trial
October 27, 2008
Medtronic Endeavour Failing to Live Up to Expectations
Analysis of: Medtronic Endeavor Heart Stent Tied to Complications | www.bloomberg.com
Author: GLG Expert Contributor
The Endeavour stent appears to have a higher restenosis rate than currently marketed Drug Eluting Stents without the improved safety profile claimed by the company.  This finding is at odds with the companies marketing message to cardiologists.  These studies, along with the introduction of...
May 27, 2008
Thrombus Aspiration in Acute MI
Analysis of: Medtronic Says Thrombus Aspiration Before Stenting Betters Survival Rates Of Myocardial Infarction Patients | www.rttnews.com
Author: GLG Expert Contributor
Mechanical thrombectomy of the coronary arteries has becoming increasingly more common with the advent of simpler aspiration catheters.  Although its use in the setting of acute myocardial infarction is even more common, it is not routine.  Randomized data indicating its effect on clinical...
May 19, 2008
Obvious answer - wrong question - NO IMPACT on prescribing
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com
Author: GLG Expert Contributor
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
February 4, 2008
Understanding the effects of statins in low risk patients.
Analysis of: Great Drug, but Does It Prolong Life? | www.nytimes.com
Author: GLG Expert Contributor
Statin therapy in lower risk populations will not have as profound an effect as in high risk subsets but still very likely has overall positive benefits.
January 25, 2008
Preventing Bariatric Surgery Deaths
Analysis of: Pinning Down Mortality Rates After Bariatric Surgery | www.medscape.com
Author: Forrest Rubenstein, Cardiac, Thoracic and Vascular Surgeon, Rubenstein Cardiovascular and Thoracic Surgery
 Bariatric surgery is a major operative procedure that caries significant morbidity and mortality risks due to the comorbid diseases seen in this patient population.  This procedure is increasing in frequency as more patients are willing to have it and more surgeons are becoming proficient. The...
January 25, 2008
Questions about bleeding, proper dose and appropriate patient subsets will limit use
Analysis of: Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration | www.pipelinereview.com
Author: GLG Expert Contributor
TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....
Samuel ButmanJanuary 17, 2008
First Impressions Carry the Day and the Year -Vytorin Loses in ENHANCE
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com
Author: Samuel Butman, Interventional Cardiologist, Verde Valley Heart LLC
The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant.   The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...
January 14, 2008
The impact on Vytorin and zetia sales will be modest reduction after the release of ENHANCE data
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com
Author: GLG Expert Contributor
Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study -  the failure to meet the trial endpoint is only a surrogate and clinical trial data...
November 23, 2007
Risk Versus Benefit
Analysis of: Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
Author: Ramin Ebrahimi, Director of Cardiac Catheterization Lab, Wadsworth VA Medical Center
The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.
October 31, 2007
Undue Pessimism
Analysis of: Phase 2 Prasugrel Studies Suspended Prior to Release of Major Phase 3 Trial | www.medscape.com
Author: GLG Expert Contributor
The devil is in the details! Far from disappointing, the protocol ammendments (dosing) based on pharmacokinetic analysis that have been effected are both prudent and reassuring. Prasugrel dosing is likely being adjusted to reflect its metabolism in various patient populations including the elderly and...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 103

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773